Results of static analyzes for selected drugs with an established position in the treatment of cardiovascular diseases Review article
Article Sidebar
Published:
Jun 30, 2019
Keywords:
ACE-I, sartans, statins, hydrochlorothiazide, side effects
Main Article Content
Abstract
Currently, in the therapy of cardiovascular diseases, numerous drugs are used to improve the prognosis of patients. These include angiotensin-converting enzyme inhibitors (ACE-I), sartans or statins. At the same time, due to the huge number of patients using these drugs, there are reports of possible side-effects. This article presents the status of possible additional effects/ side effects for ACE-I, sartans, statin and hydrochlorothiazide.
Article Details
How to Cite
Balsam , P., & Grabowski , M. (2019). Results of static analyzes for selected drugs with an established position in the treatment of cardiovascular diseases. Medycyna Faktow (J EBM), 12(2(43), 103-108. https://doi.org/10.24292/01.MF.0219.3
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Clere N., Corre I., Faure S. et al.: Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int. J. Cancer 2010; 127(10): 2279-2291.
2. Hicks B.M., Filion K.B., Yin H. et al.: Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 2018; 363: k4209.
3. Hanif K., Bid H.K., Konwar R.: Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens. Res. 2010; 33(1): 11-21.
4. Cronin-Fenton D.: Angiotensin converting enzyme inhibitors and lung cancer. Any extra risk must be balanced against the mortality benefits of ACEI use. BMJ 2018; 363: k4337.
5. Sipahi I., Debanne S.M., Rowland D.Y. et al.: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11(7): 627-636.
6. Volpe M., Azizi M., Danser A.H. et al.: Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur. Heart J. 2011; 32(1): 19-22.
7. Pfeffer M.A., Swedberg K., Granger C.B. et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759-766.
8. ARB Trialists Collaboration: Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens. 2011; 29(4): 623-635.
9. Bangalore S., Kumar S., Wetterslev J. et al.: Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342: d2234.
10. Yoon C., Yang H.S., Jeon I. et al.: Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta- analysis of observational studies. CMAJ 2011; 183(14): E1073-1084.
11. Pasternak B., Svanström H., Callréus T. et al.: Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011; 123(16): 1729-1736.
12. Huang C.C., Chan W.L., Chen Y.C. et al.: Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am. J. Cardiol. 2011; 107(7): 1028-1033.
13. Catapano A.L., Graham I., De Backer G. et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Kardiol. Pol. 2016; 74(11): 1234-1318.
14. Williams B., Mancia G., Spiering W. et al.: 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertens. 2018; 36(12): 2284-2309.
15. Pedersen S.A., Gaist D., Schmidt S.A.J. et al.: Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J. Am. Acad. Dermatol. 2018; 78(4): 673-681e9.
2. Hicks B.M., Filion K.B., Yin H. et al.: Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 2018; 363: k4209.
3. Hanif K., Bid H.K., Konwar R.: Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens. Res. 2010; 33(1): 11-21.
4. Cronin-Fenton D.: Angiotensin converting enzyme inhibitors and lung cancer. Any extra risk must be balanced against the mortality benefits of ACEI use. BMJ 2018; 363: k4337.
5. Sipahi I., Debanne S.M., Rowland D.Y. et al.: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11(7): 627-636.
6. Volpe M., Azizi M., Danser A.H. et al.: Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur. Heart J. 2011; 32(1): 19-22.
7. Pfeffer M.A., Swedberg K., Granger C.B. et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759-766.
8. ARB Trialists Collaboration: Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens. 2011; 29(4): 623-635.
9. Bangalore S., Kumar S., Wetterslev J. et al.: Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342: d2234.
10. Yoon C., Yang H.S., Jeon I. et al.: Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta- analysis of observational studies. CMAJ 2011; 183(14): E1073-1084.
11. Pasternak B., Svanström H., Callréus T. et al.: Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011; 123(16): 1729-1736.
12. Huang C.C., Chan W.L., Chen Y.C. et al.: Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am. J. Cardiol. 2011; 107(7): 1028-1033.
13. Catapano A.L., Graham I., De Backer G. et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Kardiol. Pol. 2016; 74(11): 1234-1318.
14. Williams B., Mancia G., Spiering W. et al.: 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertens. 2018; 36(12): 2284-2309.
15. Pedersen S.A., Gaist D., Schmidt S.A.J. et al.: Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J. Am. Acad. Dermatol. 2018; 78(4): 673-681e9.